Results 261 to 270 of about 319,103 (346)

Emerging Strategies for Platelet‐Modified Nanoparticles in Targeted Tumor Therapy

Advanced NanoBiomed Research, EarlyView.
This review highlights innovative strategies using platelet‐modified nanoparticles to target tumors more precisely. By mimicking platelet functions, these biomimetic carriers improve tumor homing, enhance drug delivery, and reduce immune clearance.
Chunyu Bai, Lan Sun, Yimin Cui, Huan Meng, Jiulong Li, Qian Xiang   +5 more
wiley   +1 more source

From Biomarker Discovery to Clinical Applications of Metabolomics in Glioblastoma. [PDF]

Metabolites
Šamec N, Krapež G, Skubic C, Jovčevska I, Videtič Paska A.   +4 more
europepmc   +1 more source

Glioblastoma Following Radiotherapy in a Patient with Tuberous Sclerosis —Case Report—

, 1998
Hirotaka MATSUMURA, Hiroshi Takimoto, Nobumitsu SHIMADA, Masayuki HIRATA, Takanori Ohnishi, Tōru Hayakawa   +5 more
openalex   +2 more sources

A Review on Luminescent Benzoselenadiazole Derivatives: Comparison with Benzothiadiazoles, Properties, Applications, and Trends

Chemistry – An Asian Journal, EarlyView.
This review explores the photophysical behavior and bioimaging applications of luminescent benzoselenadiazole (BSD) derivatives, in comparison with benzothiadiazole (BTD) analogues. Emerging trends highlight BSDs as promising tools in advanced phototechnology.
Brenno A. D. Neto, John Spencer, Alexandre A. M. Lapis   +2 more
wiley   +1 more source

Retraction: MicroRNA-564 is downregulated in glioblastoma and inhibited proliferation and invasion of glioblastoma cells by targeting TGF-β1. [PDF]

Oncotarget
Jiang C, Shen F, Du J, Hu Z, Li X, Su J, Wang X, Huang X.   +7 more
europepmc   +1 more source

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Nature Network Boston, 2019
Junfei Zhao, Andrew X. Chen, R. Gartrell, A. M. Silverman, Luis C. Aparicio, T. Chu, Darius D Bordbar, D. Shan, J. Samanamud, A. Mahajan, I. Filip, Rose Orenbuch, Morgan J Goetz, Jonathan T. Yamaguchi, M. Cloney, C. Horbinski, R. Lukas, J. Raizer, A. Rae, Jinzhou Yuan, P. Canoll, J. Bruce, Y. Saenger, P. Sims, F. Iwamoto, A. Sonabend, R. Rabadán   +26 more
semanticscholar   +1 more source

Approaches to repurposing reverse transcriptase antivirals in cancer

British Journal of Clinical Pharmacology, EarlyView.
This review highlights the role of reverse transcriptase (RT) inhibition in cellular regulation associated with non‐terminal repeat retrotransposons and endogenous retroviruses. Based on their pleiotropic characteristics, RT inhibitors (RTIs) are discussed as potential anticancer agents.
Richard Head, Saiful Islam, Jennifer H. Martin   +2 more
wiley   +1 more source

IGFBP-2 and IGF-II: Key Components of the Neural Stem Cell Niche? Implications for Glioblastoma Pathogenesis. [PDF]

Int J Mol Sci
Harland AJ, Perks CM.
europepmc   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

157 P53-dependent G1 arrest and P53-independent apoptosis influence the radiobiologic response of glioblastoma

, 1995
D.A. Haas-Kogan, G. Yount, M. Haas, D. Levi, Stan Kogan, Libo Hu, C. Vidair, D.F. Deen, W.C. Dewey, M.A. Israel   +9 more
openalex   +1 more source